Antibody non-specificity is characterized by undesirable off-target binding, which can severely compromise experimental accuracy and therapeutic safety. During antibody drug development, assessing this non-specificity is a critical step in characterizing a candidate's developability profile. This evaluation identifies antibodies with high specificity and low off-target potential, ultimately enhancing both the safety and efficacy profile of the lead therapeutic candidate.

Sanyou Bio Non-Specificity Evaluation Platform delivers a multi-dimensional safety profile for the antibody candidates by combining three powerful technologies, baculovirus-based cross-reactivity (BCR) evaluation, cell-based cross-reactivity (CCR) evaluation, and tissue cross-reactivity (TCR) evaluation.

This unified approach transforms off-target risk assessment from a fragmented process into a definitive, seamless workflow.

While any single method provides valuable data, it is the strategic integration of all three—beginning with BCR evaluation for early binder assessment, advancing to CCR evaluation for lead characterization, and culminating in TCR evaluation for preclinical candidate evaluation—that delivers a complete de-risking picture from discovery to regulatory submission.

By integrating these approaches, this platform provides definitive insight into antibody off-target binding—revealing its origin, context, and biological relevance to remove the uncertainties vital for antibody development.